SCHEMBL14680593

SCHEMBL14680593

CC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.56
ALDH1A1 P00352 1/20 0.54
ALOX15 P16050 1/20 0.54
CTSK P43235 8/20 0.53
CTSL P07711 4/20 0.52
CTSS P25774 4/20 0.52
CTSB P07858 3/20 0.52
CASP1 P29466 4/20 0.51
KLK7 P49862 1/20 0.51
KLK5 Q9Y337 1/20 0.51
PPARA Q07869 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6178945 0.91 SYK (0.55) SYKALDH1A1ALOX15CTSKCTSL
SCHEMBL2775895 0.91 PPARA (0.57) SYKCTSKCTSLCTSSCTSB
SCHEMBL29398102 0.91 SYK (0.57) SYKCTSKCTSLCTSSCTSB
SCHEMBL478289 0.91 PPARA (0.57) SYKCTSKCTSLCTSSCTSB
SCHEMBL1143898 0.91 PPARA (0.57) SYKCTSKCTSLCTSSCTSB
SCHEMBL19694832 0.90 KYNU (0.56) SYKALDH1A1ALOX15CTSKCTSL
Water SCHEMBL29401166 0.90 PPARA (0.56) SYKCTSKCTSLCTSSCTSB
SCHEMBL19694834 0.90 KYNU (0.56) SYKALDH1A1ALOX15CTSKCTSL
SCHEMBL4256075 0.90 KYNU (0.56) SYKALDH1A1ALOX15CTSKCTSL
Water SCHEMBL2580712 0.90 PPARA (0.56) SYKCTSKCTSLCTSSCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9388144-B2 Radiolabeled prostate specific membrane antigen inhibitors MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2016-07-12 US disclosed
US-20150078998-A1 RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS MOLECULAR INSIGHT PHARMACEUTICALS (US) 2015-03-19 US disclosed
US-8926944-B2 Radiolabeled prostate specific membrane antigen inhibitors MOLECULAR INSIGHT PHARMACEUTICALS (US) 2015-01-06 US disclosed
US-20130034494-A1 RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS MOLECULAR INSIGHT PHARMACEUTICALS 2013-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130034494-A1 RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS KLK3, FOLH1, PSMA1 SYK 4202/4885ALDH1A1 2469/4885ALOX15 4615/4885
US-20150078998-A1 RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS KLK3, FOLH1, PSMA2 SYK 4309/4885ALDH1A1 1927/4885ALOX15 4597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.